NASDAQ · VRAX
Healthcare · Biotechnology
$1.45
Down-$0.17 (-10.50%)
Updated Oct 18, 2026, 1:36 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · VRAX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
VRAX closed at $1.45 after 20 trading sessions, down 37.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $1.62 | $1.64 | $1.38 | $1.45 | 40.63K |
| Oct 15, 2026 | $1.66 | $1.76 | $1.55 | $1.6202 | 44.19K |
| Oct 14, 2026 | $1.77 | $1.78 | $1.61 | $1.65 | 38.75K |
| Oct 13, 2026 | $1.80 | $1.86 | $1.7201 | $1.7381 | 43.75K |
| Oct 12, 2026 | $1.81 | $1.8999 | $1.78 | $1.85 | 71.26K |
| Oct 9, 2026 | $1.92 | $1.94 | $1.81 | $1.87 | 88.54K |
| Oct 8, 2026 | $2.13 | $2.13 | $1.93 | $1.99 | 50.79K |
| Oct 7, 2026 | $2.02 | $2.18 | $1.83 | $2.11 | 276.36K |
| Oct 6, 2026 | $2.33 | $2.33 | $1.83 | $2.03 | 311.08K |
| Oct 5, 2026 | $2.53 | $3.34 | $2.16 | $2.40 | 2.9M |
| Oct 2, 2026 | $2.21 | $2.25 | $2.13 | $2.20 | 19.61K |
| Oct 1, 2026 | $2.18 | $2.374 | $2.18 | $2.24 | 30.88K |
| Sep 30, 2026 | $2.25 | $2.27 | $2.13 | $2.184 | 19.47K |
| Sep 29, 2026 | $2.27 | $2.395 | $2.04 | $2.23 | 97.11K |
| Sep 28, 2026 | $2.35 | $2.35 | $2.30 | $2.3144 | 5.56K |
| Sep 25, 2026 | $2.38 | $2.60 | $2.38 | $2.395 | 13.43K |
| Sep 24, 2026 | $2.2768 | $2.47 | $2.2768 | $2.44 | 20.65K |
| Sep 23, 2026 | $2.52 | $2.60 | $2.50 | $2.55 | 14.37K |
| Sep 22, 2026 | $2.38 | $2.65 | $2.2847 | $2.50 | 51.32K |
| Sep 21, 2026 | $2.48 | $2.54 | $2.145 | $2.31 | 70.84K |
The latest Smart Investors Daily articles mentioning VRAX.
Company
Market Activity
Research & News
VRAX research
Company profile and research snapshot.
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 9, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 5, 2026
Gainers Flyte Aviation, Inc. Common Stock (AMEX:VJET) stock moved upwards by 34.0% to $2.17 during Monday's after-market session. Option Care Health (NASDAQ:OPCH) shares rose 20.92% to $28.26. The market value of
ChartMill · Aug 19, 2026
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Benzinga · Aug 19, 2026
Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings came out 4
Benzinga · Aug 19, 2026
Gainers Tenon Medical (NASDAQ:TNON) stock rose 122.5% to $12.13 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.6 million. As per the news, the Q2 earnings report came
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VRAX.
No results
No recent SID articles mention VRAX.
